Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is the worst prognoses among all the malignancies. Now, gemcitabine (Gem) is the first line chemotherapeutic drug for advanced pancreatic cancer. However, Gem is usually ineffective to the PDAC because of high degree of drug resistance. Hypoxia and immune supp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tiansuo, Ren, He, Jia, Li, Chen, Jing, Xin, Wen, Yan, Fan, Li, Jing, Wang, Xiuchao, Gao, Song, Qian, Dong, Huang, Chongbiao, Hao, Jihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385849/
https://www.ncbi.nlm.nih.gov/pubmed/25544770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385849/
https://www.ncbi.nlm.nih.gov/pubmed/25544770

Ejemplares similares